Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Sintilimab Plus R-CHOP as the First-line Treatment for DLBCL Patients With TP53 Mutation and PD-L1 Positive.

NCT04023916 is registered in ClinicalTrials.gov with Chinese Academy of Medical Sciences as lead sponsor.

NCT NCT04023916
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04023916 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Sintilimab Plus R-CHOP as the First-line Treatment for DLBCL Patients With TP53 Mutation and PD-L1 Positive.
Lead sponsor
Chinese Academy of Medical Sciences
Phase
Phase 2
Overall status
Unknown status
Start date
December 1, 2019
Completion date
July 30, 2021
Enrollment
30 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma, sintilimab, tp53 mutation